April 20, 2026—PathAI and MedStar Health announced a multiyear strategic collaboration to deploy the AISight Dx digital pathology platform and AI algorithm products, including PathAI’s ArtifactDetect and TumorDetect, across MedStar’s network.
“By deploying AISight Dx and advanced AI applications, we are modernizing our pathology infrastructure in a way that makes us more connected, more efficient, and better positioned to bring innovative diagnostics into everyday practice,” Moira Larsen, MD, physician executive director, MedStar Medical Group Pathology, said in a press statement.
The partnership lays the groundwork for further collaboration as part of PathAI’s Precision Pathology Network, allowing MedStar to pursue joint research initiatives, generate real-world multimodal data, support clinical trials and biopharma partnerships, and co-develop advanced AI diagnostics.
AISight Dx is FDA cleared for primary diagnosis in the U.S. and is CE‑IVD marked for primary diagnosis in the EEA, U.K., and Switzerland.